Year: 2019
Type: article
Abstract: including suppressor of cytokine signaling 1 (SOCS1), were most frequently altered in this study.Mottok et al 1(Fig1) provide a heat map of driver mutations.Interestingly, the driver gene mutation profile in PMBL was found to be more similar to that in Hodgkin lymphoma than to that in DLBCL, underscoring the previous gene expression observations and potentially blended biology of PMBL, which may represent an intermediate malignancy between Hodgkin and non-Hodgkin lymphoma.Altogether, Mottok et al provided a detailed characterization of the genomic landscape and correlations with gene expression levels of a large, well-defined cohort of patients with PMBL that should facilitate our understanding of PMBL biology, support the development of accurate diagnostics, and encourage design of therapeutic approaches aimed at restoring tumor immune recognition and targeting other vulnerabilities.9,10 Conflict-of-interest disclosure: L.M.R. is an inventor on a patented, nonlicensed, assay known as the Lymph3Cx.n
Source: Blood
Authors: Bridget K. Marcellino, John Mascarenhas
Institution: Icahn School of Medicine at Mount Sinai
Language: English
Subfield: Genetics
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W2971492282